The grades of 5 Biotechnology stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.

Loxo Oncology Inc (LOXO) improves from a B to a A rating this week. The company also gets A’s in earnings surprise. For more information, get Portfolio Grader’s complete analysis of LOXO stock.

This week, La Jolla Pharmaceutical Company’s (LJPC) ratings are up from a C last week to a B. For more information, get Portfolio Grader’s complete analysis of LJPC stock.

Lexicon Pharmaceuticals, Inc. (LXRX) earns a A this week, jumping up from last week’s grade of B. Lexicon Pharmaceuticals, Inc. researches treatments for diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders, and ophthalmic disease. The company also gets A’s in sales growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of LXRX stock.

The rating of Celator Pharmaceuticals, Inc. (CPXX) moves up this week, rising from a C to a B. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of CPXX stock.

This week, Athersys, Inc. (ATHX) pushes up from a C to a B rating. Athersys, Inc. is a biopharmaceutical company that engages in the discovery and development of therapeutic products in various disease areas in the United States. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of ATHX stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.